Abcellera Intangible Assets vs Current Deferred Revenue Analysis
ABCL Stock | USD 3.85 0.07 1.85% |
Abcellera BiologicsInc financial indicator trend analysis is way more than just evaluating Abcellera BiologicsInc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Abcellera BiologicsInc is a good investment. Please check the relationship between Abcellera BiologicsInc Intangible Assets and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
Intangible Assets vs Current Deferred Revenue
Intangible Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Abcellera BiologicsInc Intangible Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have no relationship.
The correlation between Abcellera BiologicsInc's Intangible Assets and Current Deferred Revenue is 0.07. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Abcellera BiologicsInc, assuming nothing else is changed. The correlation between historical values of Abcellera BiologicsInc's Intangible Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Abcellera BiologicsInc are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Intangible Assets i.e., Abcellera BiologicsInc's Intangible Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.07 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Abcellera BiologicsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Abcellera BiologicsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.At this time, Abcellera BiologicsInc's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 1.68 this year, although the value of Tax Provision is projected to rise to (26.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.8M | 59.7M | 30.9M | 20.4M | Interest Income | 3.3M | 16.1M | 42.2M | 44.4M |
Abcellera BiologicsInc fundamental ratios Correlations
Click cells to compare fundamentals
Abcellera BiologicsInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Abcellera BiologicsInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.5M | 1.0B | 1.3B | 1.5B | 1.5B | 989.6M | |
Short Long Term Debt Total | 6.9M | 6.1M | 36.4M | 82.3M | 77.4M | 39.0M | |
Other Current Liab | 129.3K | 76.7M | 77.5M | 58.0M | 61.3M | 50.2M | |
Total Current Liabilities | 7.9M | 103.5M | 120.7M | 118.3M | 119.0M | 87.2M | |
Total Stockholder Equity | 10.3M | 830.5M | 1.0B | 1.2B | 1.2B | 781.7M | |
Other Liab | 1.3M | 65.6M | 134.0M | 112.6M | 129.5M | 69.6M | |
Net Tangible Assets | 2.7M | 683.9M | 829.5M | 1.1B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 8.5M | 17.9M | 111.6M | 217.3M | 287.7M | 302.1M | |
Current Deferred Revenue | 3.2M | 6.6M | 7.5M | 21.6M | 26.1M | 27.4M | |
Net Debt | (661.9K) | (588.0M) | (439.7M) | (304.3M) | (55.9M) | (58.7M) | |
Retained Earnings | (4.7M) | 114.2M | 267.7M | 426.2M | 279.8M | 198.1M | |
Accounts Payable | 1.6M | 20.0M | 32.0M | 33.2M | 25.5M | 20.9M | |
Cash | 7.6M | 594.1M | 476.1M | 386.5M | 133.3M | 126.7M | |
Non Current Assets Total | 10.8M | 192.2M | 388.8M | 515.4M | 616.1M | 317.1M | |
Cash And Short Term Investments | 7.6M | 594.1M | 723.0M | 886.5M | 760.6M | 546.7M | |
Net Receivables | 4.4M | 213.2M | 160.6M | 38.6M | 64.4M | 89.0M | |
Common Stock Total Equity | 5.1M | 710.4M | 722.4M | 734.4M | 844.5M | 479.0M | |
Common Stock Shares Outstanding | 154.1M | 269.5M | 318.3M | 314.8M | 289.2M | 290.3M | |
Liabilities And Stockholders Equity | 23.5M | 1.0B | 1.3B | 1.5B | 1.5B | 989.6M | |
Non Current Liabilities Total | 5.3M | 71.5M | 172.2M | 189.3M | 216.8M | 120.7M | |
Capital Lease Obligations | 3.1M | 3.7M | 36.4M | 82.3M | 77.4M | 81.2M | |
Other Current Assets | 1.8M | 6.0M | 21.2M | 75.4M | 20.9M | 23.1M | |
Other Stockholder Equity | 2.3M | 5.9M | 35.4M | 74.1M | 121.1M | 127.1M | |
Total Liab | 13.2M | 175.0M | 292.8M | 307.6M | 335.8M | 208.0M | |
Net Invested Capital | 6.5M | 832.9M | 1.0B | 1.2B | 1.2B | 780.7M | |
Property Plant And Equipment Gross | 8.5M | 17.9M | 121.4M | 235.7M | 318.3M | 334.2M | |
Total Current Assets | 12.6M | 813.3M | 929.8M | 1.0B | 872.0M | 672.5M | |
Capital Stock | 12.7M | 710.4M | 722.4M | 734.4M | 753.2M | 540.0M | |
Net Working Capital | 4.7M | 709.8M | 809.1M | 907.2M | 753.0M | 585.3M | |
Short Term Debt | 2.9M | 190K | 3.7M | 5.6M | 6.2M | 3.9M | |
Common Stock | 5.1M | 710.4M | 722.4M | 734.4M | 753.2M | 537.3M | |
Property Plant Equipment | 8.5M | 17.9M | 111.6M | 217.3M | 249.8M | 262.3M |
Pair Trading with Abcellera BiologicsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abcellera BiologicsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abcellera BiologicsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Abcellera Stock
0.88 | EVOK | Evoke Pharma | PairCorr |
Moving against Abcellera Stock
0.68 | ELYM | Eliem Therapeutics Trending | PairCorr |
0.67 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
0.57 | HCWB | HCW Biologics | PairCorr |
0.56 | KRYS | Krystal Biotech Earnings Call This Week | PairCorr |
0.55 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Abcellera BiologicsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abcellera BiologicsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abcellera BiologicsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abcellera BiologicsInc to buy it.
The correlation of Abcellera BiologicsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abcellera BiologicsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abcellera BiologicsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abcellera BiologicsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.Note that the Abcellera BiologicsInc information on this page should be used as a complementary analysis to other Abcellera BiologicsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Abcellera Stock analysis
When running Abcellera BiologicsInc's price analysis, check to measure Abcellera BiologicsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera BiologicsInc is operating at the current time. Most of Abcellera BiologicsInc's value examination focuses on studying past and present price action to predict the probability of Abcellera BiologicsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abcellera BiologicsInc's price. Additionally, you may evaluate how the addition of Abcellera BiologicsInc to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Abcellera BiologicsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera BiologicsInc. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera BiologicsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.51) | Revenue Per Share 0.131 | Quarterly Revenue Growth (0.57) | Return On Assets (0.1) |
The market value of Abcellera BiologicsInc is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera BiologicsInc's value that differs from its market value or its book value, called intrinsic value, which is Abcellera BiologicsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera BiologicsInc's market value can be influenced by many factors that don't directly affect Abcellera BiologicsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera BiologicsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera BiologicsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera BiologicsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.